REG - GlaxoSmithKline PLC - Director/PDMR Shareholding
18/02/2022 17:03
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220218:nRSR1852Ca&default-theme=true
RNS Number : 1852C GlaxoSmithKline PLC 18 February 2022
GlaxoSmithKline plc (the 'Company')
Vesting of Performance Share Plan Awards
This notification sets out the vesting details of awards over Ordinary Shares
and American Depositary Shares ('ADSs') made to Persons Discharging Managerial
Responsibilities ('PDMRs') and their Persons Closely Associated ('PCAs') in
2019 under the GlaxoSmithKline 2017 Performance Share Plan ('PSP'), which were
subject to relevant business performance conditions, and the subsequent sale
of ordinary shares and ADSs to meet tax liabilities. Awards were made in
2019 and the three-year performance period commenced on 1 January 2019 and
ended on 31 December 2021. The vested shares for the Executive Directors are
now subject to an additional two-year vesting period.
The performance measure vesting details for those PDMRs who received awards in
2019 are set out in the following table.
Outcome and Vesting Level
Portion of the Award Measure and Outcome % of maximum % of award
1/3rd Adjusted Free Cash Flow - For the three-year period, the Company achieved 100 33.33
Adjusted Free Cash Flow calculated in accordance with the principles for the
measure of £14.53bn, which is above the level of £13.20bn required for
maximum vesting.
Adjustments to the original target and vesting schedule were communicated in
the 2020 Annual Report and will be set out in the 2021 Annual Report.
1/3rd Total Shareholder Return - For the three years ending 31 December 2021, the 0 0
Company's Total Shareholder Return ranked 10th, which is below the threshold
vesting level against a comparator group of 10 global pharmaceutical companies
including GSK.
1/3rd R&D New Products - For the three-year period, the Company achieved New 74 24.66
Product sales calculated in accordance with the principles for the measure of
£11.12bn, which is slightly below the level of £11.14bn required for 75%
vesting. The threshold vesting level was £10.02bn.
Total vesting for 2019 award 58 57.99
Lapsed 42
The notifications that follow are for awards made to PDMRs and their PCAs and
detail the PSP conditional awards that vested, including dividends accrued, on
16 February 2022. The balance of the award made to each PDMR and PCA has
lapsed.
The closing prices of Ordinary Shares and of ADSs of GlaxoSmithKline plc on
the vesting date were £15.76 and $43.39.
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms E Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2019 under the
Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 274,480
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr I Mackay
b) Position/status Chief Financial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2019 under the
Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 152,815
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr H Barron
b) Position/status Chief Scientific Officer and President, R&D
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W1053
b) Nature of the transaction The number of ADSs vesting on awards granted in 2019 under the Company's 2017
Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
$0.00 146,831
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr H Barron
b) Position/status Chief Scientific Officer and President, R&D
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W1053
b) Nature of the transaction The sale of ADSs to meet tax liabilities for the vesting of awards granted in
2019 under the Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
$43.3404 79,172
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr R Connor
b) Position/status President, Vaccines and Global Health
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2019 under the
Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 119,780
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr R Connor
b) Position/status President, Vaccines and Global Health
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2019 under the Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£15.8269 56,297
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms D Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Following the vesting on 16 February 2022 of awards granted in 2019 under the
Company's 2017 Performance Share Plan, Ms Conrad will receive a cash payment
of £126,710.48 less applicable tax withholding in respect of 8,006 notional
ordinary shares.
c) Price(s) and volume(s) Price(s) Volume(s)
£15.8269 8,006
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr J Ford
b) Position/status SVP and General Counsel
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W1053
b) Nature of the transaction The number of ADSs vesting on awards granted in 2019 under the Company's 2017
Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
$0.00 46,446
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr J Ford
b) Position/status SVP and General Counsel
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W1053
b) Nature of the transaction The sale of ADSs to meet tax liabilities for the vesting of awards granted in
2019 under the Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
$43.3404 21,830
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms S Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2019 under the
Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 8,006
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms S Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2019 under the Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£15.8269 3,763
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr D Jackson
b) Position/status PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2019 under the
Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 3,780
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr D Jackson
b) Position/status PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2019 under the Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£15.8269 1,777
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr B McNamara
b) Position/status CEO, GSK Consumer Healthcare
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W1053
b) Nature of the transaction The number of ADSs vesting on awards granted in 2019 under the Company's 2017
Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
$0.00 67,075
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr B McNamara
b) Position/status CEO, GSK Consumer Healthcare
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W1053
b) Nature of the transaction The sale of ADSs to meet tax liabilities for the vesting of awards granted in
2019 under the Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
$43.3404 33,974
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr L Miels
b) Position/status Chief Commercial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2019 under the
Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 134,163
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr L Miels
b) Position/status Chief Commercial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2019 under the Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£15.8269 4,008
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms S Ramakrishnan
b) Position/status Chief Technology and Digital Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W1053
b) Nature of the transaction The number of ADSs vesting on awards granted in 2019 under the Company's 2017
Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
$0.00 4,558
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms S Ramakrishnan
b) Position/status Chief Technology and Digital Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W1053
b) Nature of the transaction The sale of ADSs to meet tax liabilities for the vesting of awards granted in
2019 under the Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
$43.3404 2,444
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr D Redfern
b) Position/status Chief Strategy Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2019 under the
Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 110,567
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr D Redfern
b) Position/status Chief Strategy Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2019 under the Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£15.8269 51,967
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr R Simard
b) Position/status President, Pharmaceuticals Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2019 under the
Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 64,497
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr R Simard
b) Position/status President, Pharmaceuticals Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2019 under the Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£15.8269 30,314
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr P Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2019 under the
Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 50,497
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr P Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2019 under the Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£15.8269 23,734
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms D Waterhouse
b) Position/status CEO, ViiV Healthcare
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2019 under the
Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 10,978
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms D Waterhouse
b) Position/status CEO, ViiV Healthcare
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2019 under the Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£15.8269 5,160
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms V Whyte
b) Position/status Company Secretary
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2019 under the
Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 8,006
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms V Whyte
b) Position/status Company Secretary
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2019 under the Company's 2017 Performance Share Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£15.8269 3,763
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-02-16
f) Place of the transaction London Stock Exchange (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHQVLFFLLLLBBDRecent news on GSK
See all newsREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Exdensur (depemokimab ulla) approved by US FDA
AnnouncementREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Exdensur (depemokimab) UK MHRA approval
AnnouncementREG - GSK PLC - Transaction in Own Shares
Announcement